The startup operates a protein engineering platform that utilizes engineered cytokines to induce sustained immunological tolerance for treating autoimmune diseases. This approach enables healthcare professionals to manage autoimmune and inflammatory disorders without the need for immunosuppressive therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for autoimmune diseases often rely on broad immunosuppression, leading to negative side effects and incomplete disease management. These therapies can leave patients vulnerable to infections and other complications while failing to address the underlying cause of the autoimmune response.
Solution
HeioThera is developing a protein engineering platform focused on engineered cytokines to induce immunological tolerance, offering a novel approach to treating autoimmune and inflammatory disorders. Their "platform-in-a-molecule" aims to upregulate the anti-inflammatory system, thereby calming the unchecked immune systems of individuals suffering from autoimmune diseases. By leveraging the body’s natural mechanisms, HeioThera's approach seeks to restore balance to the immune system, offering a potential alternative to aggressive immunosuppression. This strategy targets the underlying cause of autoimmune diseases by inducing a tolerogenic response, potentially leading to more durable and targeted therapeutic outcomes. The platform has potential application across a range of autoimmune conditions, from rare diseases like scleroderma to more prevalent conditions like rheumatoid arthritis and Crohn's disease. Proof-of-concept experiments are underway, with animal models planned to further validate the mechanism of action.
Target Audience
The primary target audience includes individuals with autoimmune diseases, as well as healthcare professionals specializing in immunology, rheumatology, and related fields seeking novel therapeutic options.
Features
- Engineered cytokines designed to enhance the anti-inflammatory cascade
- Induction of a tolerogenic response to re-establish immune balance
- Potential application for multiple sclerosis, diabetic wound healing, atherosclerosis, fibrosis, type-1 diabetes prevention, rheumatoid arthritis, scleroderma, ischemic stroke, diabetic peripheral neuropathy, Crohn’s disease, and IBD
- Focus on addressing the underlying cause of autoimmune disorders rather than broad immunosuppression